Tuthill Porsche, the UK’s premier historic Porsche preparation expert, is delighted to announce a new sponsorship agreement with British pharmaceutical firm CST Pharma Ltd.
CST Pharma Ltd, a well-known pharmaceutical supplier based in the West Midlands, will become title sponsor of both the Tuthill Porsche Challenge – the only one-make rally series in the world for historic Porsches – and the renowned Tuthill Porsche Ice Driving course in Norway, with immediate effect.
The company’s name will appear on all the cars and branding, giving CST Pharma a wider international aspect and an even closer association with the adrenaline rush of motorsport.
CST Pharma is one of the leading pharmaceutical suppliers in its field, and the company is aiming to benefit from the wide range of people that it will come into contact with through the activities of Tuthill Porsche – both on rally stages and frozen lakes.
Daniel O’Connor from CST Pharma commented: “Like many people, I’ve admired the classic Porsche 911 and the brilliant preparation from Tuthill Porsche for many years, so it seemed natural to link up in this way as title sponsor. Their uncompromising attention to detail and emphasis on complete quality is a perfect match with our own philosophy, making it an excellent partnership. We very much look forward to seeing our logo on what we think are the most exciting cars in the world. Through the Challenge and also the ice-driving in Norway, we see motorsport sponsorship as an excellent way to expand our brand reach.”
Tuthill Porsche director Richard Tuthill added: “I’m absolutely delighted by this partnership with CST Pharma, which helps increase the visibility of both the Porsche Challenge and Norway Ice Driving: two of our most high-profile activities. I know all the people concerned well, and they have a real passion for motorsport as well as for business. We’re very much looking forward to seeing them out on events: I’m sure that this is just the start of a long-term collaboration that will be extremely mutually beneficial.”